Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 191

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 191
---
ELIPHARM        
 ACQUISITION INC. |             |
| By               | /s/         
 Erez Aminov |
| Name:            | Erez        
 Aminov      |
| Title:           | President   |

| TELI                  
 PHARMACEUTICALS, INC. |                 |
| By                    | /s/             
 William McNulty |
| Name:                 | William         
 McNulty         |
| Title:                | CEO             |

<div align='center'>[Signature page to Agreement and Plan of Merger]</div>

| 35 |

<div align='center'>Schedule A to Agreement and Plan of Merger</div>

At the effective time of the Merger (the “Effective Time”), (1) each outstanding share of common stock of TELI, $0.0001 par value per share (“TELI Common Stock”), will be converted into the right to receive such number of shares of common stock of the Company, $0.0001 par value per share (“Company Common Stock”) as is calculated in to the Exchange Ratio (the “Closing”). The Exchange Ratio is calculated using the relative company valuations of each of the Company and TELI, as determined by a third-party valuation firm, and whereas the amount of TELI share value is calculated on an as-issued (non-dilution) basis and the TELI share value is calculated on a fully diluted basis to include all issued TELI options and warrants. The amount of Company Common Stock issued to TELI holders shall not exceed the amount of Company Common Stock outstanding as-of November 3, 2025.

Annex B

| Moore Financial Consulting |

| Teli.Valuation | November 2025Page 2 of 24 |

Dear Sir,

Upon your request, Moore Financial Consulting Ltd. (hereinafter: “MFC”), performed a valuation of a corporation that will hold the international rights to Telomir’s technology, licensed by Miralogx (“Teli”, “the Company”).

Our study was performed based on the following:

| ● | Data                             
 regarding the costs and expenses |
| ● | Public                           
 information                      |

This report was prepared based on information provided to us and from discussions held with the Company’s management. We did not verify the accuracy, reliability or completeness of the information provided and the procedures we used while performing the valuation do not constitute an audit or review made under any generally accepted auditing standards.

Our professional fees for this study were not subject to the